Anti-S12A3/ SLC12A3/ NCC monoclonal antibody
Anti-S12A3/ SLC12A3/ NCC antibody for FACS & in-vivo assay
Go to SLC12A3/SLC12A3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T84886-Ab-1/ GM-Tg-hg-T84886-Ab-2 | Anti-Human SLC12A3 monoclonal antibody | Human |
GM-Tg-rg-T84886-Ab-1/ GM-Tg-rg-T84886-Ab-2 | Anti-Rat SLC12A3 monoclonal antibody | Rat |
GM-Tg-mg-T84886-Ab-1/ GM-Tg-mg-T84886-Ab-2 | Anti-Mouse SLC12A3 monoclonal antibody | Mouse |
GM-Tg-cynog-T84886-Ab-1/ GM-Tg-cynog-T84886-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC12A3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T84886-Ab-1/ GM-Tg-felg-T84886-Ab-2 | Anti-Feline SLC12A3 monoclonal antibody | Feline |
GM-Tg-cang-T84886-Ab-1/ GM-Tg-cang-T84886-Ab-2 | Anti-Canine SLC12A3 monoclonal antibody | Canine |
GM-Tg-bovg-T84886-Ab-1/ GM-Tg-bovg-T84886-Ab-2 | Anti-Bovine SLC12A3 monoclonal antibody | Bovine |
GM-Tg-equg-T84886-Ab-1/ GM-Tg-equg-T84886-Ab-2 | Anti-Equine SLC12A3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T84886-Ab-1/ GM-Tg-hg-T84886-Ab-2; GM-Tg-rg-T84886-Ab-1/ GM-Tg-rg-T84886-Ab-2; GM-Tg-mg-T84886-Ab-1/ GM-Tg-mg-T84886-Ab-2; GM-Tg-cynog-T84886-Ab-1/ GM-Tg-cynog-T84886-Ab-2; GM-Tg-felg-T84886-Ab-1/ GM-Tg-felg-T84886-Ab-2; GM-Tg-cang-T84886-Ab-1/ GM-Tg-cang-T84886-Ab-2; GM-Tg-bovg-T84886-Ab-1/ GM-Tg-bovg-T84886-Ab-2; GM-Tg-equg-T84886-Ab-1/ GM-Tg-equg-T84886-Ab-2 |
Products Name | Anti-SLC12A3 monoclonal antibody |
Format | mab |
Target Name | SLC12A3 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-SLC12A3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species S12A3/ SLC12A3/ NCC VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP001732 | human SLC12A3 Lentivirus plasmid |
ORF Viral Vector | vGMLP001732 | human SLC12A3 Lentivirus particle |
Target information
Target ID | GM-T84886 |
Target Name | SLC12A3 |
Gene ID | 6559,20497,54300,703090,478118,101082284,404171,100051953 |
Gene Symbol and Synonyms | NCC,NCCT,SLC12A3,TSC |
Uniprot Accession | P55017,P55018 |
Uniprot Entry Name | S12A3_HUMAN,S12A3_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000070915 |
Target Classification | N/A |
The target: SLC12A3, gene name: SLC12A3, also named as NCC, NCCT, TSC. This gene encodes a renal thiazide-sensitive sodium-chloride cotransporter that is important for electrolyte homeostasis. This cotransporter mediates sodium and chloride reabsorption in the distal convoluted tubule. Mutations in this gene cause Gitelman syndrome, a disease similar to Bartter's syndrome, that is characterized by hypokalemic alkalosis combined with hypomagnesemia, low urinary calcium, and increased renin activity associated with normal blood pressure. This cotransporter is the target for thiazide diuretics that are used for treating high blood pressure. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.